aid: candid-therapeutics
name: Candid Therapeutics
description: 'Candid Therapeutics is a San Diego, California clinical-stage biotechnology
  company developing T-cell engager (TCE) antibody therapies for autoimmune and inflammatory
  diseases. Launched publicly in September 2024 with a $370 million Series A financing
  and assembled by acquiring Vignette Bio and TRC 2004, Candid in-licenses differentiated
  bispecific TCE assets and advances them through US clinical development. Its approach
  redirects T-cells to selectively deplete autoreactive B-cells, aiming for deeper
  and more durable depletion than conventional antibody therapy without the manufacturing
  burden of cell therapy. Its lead investigational asset, cizutamig, is a BCMA x CD3
  bispecific antibody. UCB completed its acquisition of Candid Therapeutics on 17 June
  2026 for up to $2.2 billion ($2.0 billion upfront plus up to $200 million in milestones),
  and the company now operates as part of UCB. Candid Therapeutics publishes no public
  API, developer portal, SDK, or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/candid-therapeutics/refs/heads/main/apis.yml
image: https://www.candidrx.com/wp-content/uploads/2024/08/candid-logo.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-08-02'
modified: '2026-08-02'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Autoimmune Disease
- Clinical Trials
- Therapeutics
- Antibodies
- Drug Development
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/candid-therapeutics-domain-security.yml
- type: Website
  url: https://www.candidrx.com/
- type: About
  url: https://www.candidrx.com/about/overview/
- type: TermsOfService
  url: https://www.candidrx.com/terms-of-use/
- type: Accessibility
  url: https://www.candidrx.com/accessibility-statement/
- type: BoardOfDirectors
  url: https://www.candidrx.com/about/board-of-directors/
- type: SecondaryMarket
  url: https://forgeglobal.com/candid-therapeutics_stock/
- type: ParentCompany
  url: https://www.ucb.com/
- type: LLMsTxt
  url: llms/candid-therapeutics-llms.txt
x-acquisition:
  acquirer: UCB
  acquirer_slug: ucb
  announced: '2026-05-03'
  completed: '2026-06-17'
  value_usd: 2200000000
  terms: $2.0B upfront plus up to $200M in milestones
  source: https://www.ucb.com/newsroom/press-releases/article/ucb-completes-acquisition-of-candid-therapeutics-strengthening-next-generation-immunology-pipeline
x-enrichment:
  date: '2026-08-02'
  status: minimal
  artifacts_added: 3
  pass: local-v1